14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PROK vs EVMN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over ProKidney Corp. Class A (PROK) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). PROK carries a Unified Composite Score of 54.0/100 (HOLD) at $1.04 (N/M Forward P/E, -24871.4% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While PROK currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -24871.4% operating margin) and revenue trajectory (+0.0% vs. -19.8% YoY).
Technical & Structure Timing Caution: PROK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PROK vs EVMN Key Questions & Quantitative Answers
As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over ProKidney Corp. Class A (PROK) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). PROK carries a Unified Composite Score of 54.0/100 (HOLD) at $1.04 (N/M Forward P/E, -24871.4% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PROK currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -24871.4% operating margin) and revenue trajectory (+0.0% vs. -19.8% YoY). Technical & Structure Timing Caution: PROK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PROK leads the Growth & Scale pillar: PROK posts -19.8% YoY revenue growth and +0.0% YoY earnings growth on $775,000 TTM revenue (100.0% gross margin, -24871.4% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 2-period historical trajectory (FY2024 to FY2025), PROK cumulative revenue shifted N/A while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, PROK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.
PROK and EVMN trade at balanced relative valuation multiples. PROK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PROK (-73.4% ROE) versus EVMN (-69.5% ROE) capital efficiency.
In options market volatility and institutional positioning, PROK carries 446.3% implied volatility (51st %ile, Balanced (25th–60th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 92% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.